docetaxel anhydrous has been researched along with dasatinib in 14 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (dasatinib) | Trials (dasatinib) | Recent Studies (post-2010) (dasatinib) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 2,707 | 216 | 2,081 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 12 (85.71) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brown, LG; Corey, E; Koreckij, T; Nguyen, H; Vessella, RL; Yu, EY | 1 |
| Fan, X; Guo, B; Guo, W; Jiang, Y; Li, K; Liang, S; Qin, S; Wang, L; Wang, R; Zhao, Y | 1 |
| Agrawal, S; Araujo, JC; Armstrong, AJ; Braud, EL; Gallick, GE; Logothetis, CJ; Lonberg, M; Mathew, P; Paliwal, P; Posadas, E; Trudel, GC | 1 |
| Cianchetti, M; Forastiere, A; Gunn, GB; Marur, S; McNutt, T; Rao, N; Ricchetti, F; Sanguineti, G; Sormani, MP; Wu, B | 1 |
| Araujo, JC; Chatterji, T; Dayyani, F; Gallick, GE; Logothetis, CJ; Song, JH; Trudel, GC; Varkaris, A | 1 |
| Araujo, JC; Armstrong, AJ; Begbie, S; Bellmunt, J; Cheng, S; de Bono, JS; Durham, S; Efstathiou, E; Gallardo, E; Goebell, PJ; Heidenreich, A; Hong, JH; Logothetis, CJ; Matveev, VB; McCaffrey, J; Morris, MJ; Oudard, S; Paliwal, P; Richardet, E; Saad, F; Serrano, SV; Sizer, B; Trudel, GC; Wilding, G; Yu, EY | 1 |
| Adams, DJ; Grace, L; Jia, J; Murphy, SK; Nixon, AB; Secord, AA; Teoh, D | 1 |
| Carducci, MA; Chi, KN; Hotte, SJ; Ivy, SP; Kamel-Reid, S; Kavsak, P; Kollmannsberger, CK; Mukherjee, SD; Siu, LL; Smith, DC; Spreafico, A; Sridhar, SS; Sukhai, MA; Takebe, N; Wang, L; Wong, TS | 1 |
| Bertaglia, V; Buttigliero, C; Di Maio, M; Scagliotti, GV; Tucci, M; Vignani, F | 1 |
| Balaji, U; Conway, W; Eslinger, C; Knudsen, ES; McMillan, E; Mills, GB; O'Reilly, EM; Posner, B; Witkiewicz, AK | 1 |
| Cui, Z; Shi, B; Wang, T; Zhang, W | 1 |
2 review(s) available for docetaxel anhydrous and dasatinib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Dasatinib; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Taxoids; Zoledronic Acid | 2016 |
3 trial(s) available for docetaxel anhydrous and dasatinib
| Article | Year |
|---|---|
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Castration; Dasatinib; Docetaxel; Drug Administration Schedule; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Taxoids; Thiazoles | 2012 |
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dasatinib; Disease Progression; Docetaxel; Double-Blind Method; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Taxoids; Thiazoles; Treatment Failure | 2013 |
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Collagen Type I; Dasatinib; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mutation; Peptides; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sequence Analysis, DNA; src-Family Kinases; Taxoids; Thiazoles; Treatment Outcome | 2014 |
9 other study(ies) available for docetaxel anhydrous and dasatinib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Neoplasms; Cell Line, Tumor; Dasatinib; Docetaxel; Humans; Male; Mice; Mice, SCID; Osteolysis; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Taxoids; Thiazoles; Xenograft Model Antitumor Assays | 2009 |
Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Calcium-Binding Proteins; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Proliferation; Dasatinib; Docetaxel; Drug Synergism; Esophageal Neoplasms; Female; Humans; Mad2 Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Repressor Proteins; src-Family Kinases; Taxoids; Thiazoles; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Confidence Intervals; Dasatinib; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Mouth Mucosa; Odds Ratio; Organs at Risk; Oropharyngeal Neoplasms; Pyrimidines; Radiography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Stomatitis; Taxoids; Thiazoles; Tumor Burden | 2012 |
Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer.
Topics: 3T3 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dasatinib; Docetaxel; Enzyme-Linked Immunosorbent Assay; Humans; Insulin-Like Growth Factor I; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Osteoblasts; Prostatic Neoplasms; Pyrimidines; Taxoids; Thiazoles; Xenograft Model Antitumor Assays | 2013 |
Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Dasatinib; Deoxycytidine; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gemcitabine; Humans; Paxillin; Pyrimidines; Signal Transduction; src-Family Kinases; Taxoids; Thiazoles; Topotecan | 2014 |
Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Dasatinib; Docetaxel; Drug Resistance, Neoplasm; Everolimus; Exome; Humans; Mice; Models, Genetic; Models, Statistical; Pancreatic Neoplasms; Precision Medicine; Prognosis; Pyridones; Pyrimidinones; Taxoids; Xenograft Model Antitumor Assays | 2016 |
The therapeutic and prognostic role of cuproptosis-related genes in triple negative breast cancer.
Topics: Apoptosis; Copper; Dasatinib; Docetaxel; Humans; Mutation; Prognosis; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2023 |